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Abstract
AIM
To evaluate the significance of resection margin width in 
the management of hepatocholangiocarcinoma (HCC-CC).
METHODS
Data of consecutive patients who underwent hepa-
tectomy for hepatic malignancies in the period from 
1995 to 2014 were reviewed. Patients with pathologically 
confirmed HCC-CC were included for analysis. Demo-
graphic, biochemical, operative and pathological data 
were analyzed against survival outcomes.
RESULTS
Forty-two patients were included for analysis. The 
median age was 53.5 years. There were 29 males. 
Hepatitis B virus was identified in 73.8% of the patients. 
Most patients had preserved liver function. The median 
preoperative indocyanine green retention rate at 15 min 
was 10.2%. The median tumor size was 6.5 cm. Major 
hepatectomy was required in over 70% of the patients. 
Hepaticojejunostomy was performed in 6 patients. 
No hospital death occurred. The median hospital stay 
was 13 d. The median follow-up period was 32 mo. 
The 5-year disease-free survival and overall survival 
were 23.6% and 35.4% respectively. Multifocality was 
the only independent factor associated with disease-
free survival [P  < 0.001, odds ratio 4, 95% confidence 
interval (CI): 1.9-8.0]. In patients with multifocal tumor 
(n  = 20), resection margin of ≥ 1 cm was associated 
with improved 1-year disease-free survival (40% vs  0%; 
log-rank, P  = 0.012).
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CONCLUSION
HCC-CC is a rare disease with poor prognosis. Resection 
margin of 1 cm or above was associated with improved 
survival outcome in patients with multifocal HCC-CC.
Key words: Hepatocholangiocarcinoma; Hepatocellular 
cholangiocarcinoma; Survival; Hepatectomy; Resection 
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Core tip: A retrospective review of all patients who 
had undergone curative resection for hepatocholan-
giocarcinoma in the last 20 years was performed in a 
university center. The 5-year disease-free and overall 
survival were 23.6% and 35.4% respectively. Various 
patient and disease factors were investigated with 
respect to their effect to disease free and overall survival 
using cox regression analysis. Multifocality was the only 
independent factor associated with disease-free survival 
(P  < 0.001). In a subgroup of patient (n  = 20) who 
had multifocal tumor, resection margin of ≥ 1 cm was 
associated with improved 1-year disease-free survival 
(40% vs 0%, P = 0.012).
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INTRODUCTION
Hepatocholangiocarcinoma (HCC-CC) is a rare disease 
entity contributing to 1%-3% of primary hepatic malig-
nancies[1-4]. Histologically, tumor cells of hepatocyte 
and bile ductal epithelial origins are identified in HCC-
CC[5]. While “pseudoglandular” structures can as well 
be observed in other hepatocellular carcinoma (HCC) 
variants[6], genuine HCC-CC should demonstrate true 
glandular structures with mucin production[7]. Since 
the first description of HCC-CC in 1949 by Allen and 
Lisa[8], 3 subtypes of the disease were established: 
Type 1, double separate tumors - HCC and intrahepatic 
cholangiocarcinoma (ICC) - in the same liver; type 2, 
the presence of HCC and ICC in a continuum; type 3, 
intermingling of HCC and ICC cells[8]. In 1985, Goodman 
et al[9] revised the classification with new descriptions of 3 
types of HCC-CC: The collision type, the transitional type, 
and fibrolamellar HCC with mucin-producing pseudoglands. 
Later, the World Health Organization redefined HCC-CC as 
a distinct tumor with intimate and unequivocal fusion of 
HCC and ICC cells[10]. The disease’s clinical outcomes and 
prognostic factors have barely been studied. The median 
survival after HCC-CC resection varied from study to study, 
from 12 to 48 mo[11-15]. This disparity may be partially 
explained by the heterogeneity in diagnostic criteria for 
HCC-CC in the studies. The inclusion of HCC variants 
(which do not contain genuine ICC components) and the 
collision type of HCC-CC (which is no longer regarded 
as HCC-CC according to the World Health Organization) 
probably led to data contamination and resulted in 
difference in prognosis[16].
The width of resection margin had been shown 
to affect the oncological outcomes of hepatectomy for 
HCC[17-19] and ICC[20,21]. In a prospective randomized trial 
involving 169 patients by Shi et al[19], patients who were 
randomized to the narrow margin group (1 cm) had 
significantly inferior 5-year overall survival when compared 
with patients who had HCC resection with wide margin 
(2 cm) (49.1% vs 74.9%). For the role of resection 
margin in ICC, Farges et al[21] demonstrated a significant 
correlation between resection margin and median survival 
in a subgroup of node-negative patients (≤ 1 mm: 15 
mo, 2-4 mm: 36 mo, 5-9 mm: 57 mo, ≥ 10 mm: 64 mo; 
P < 0.001). In a recent article by our center, patients with 
early ICC were shown to benefit from resection margin 
of over 1 cm[20]. Nonetheless, the role of resection margin 
in management of HCC-CC remains to be defined. This 
retrospective study aimed to elucidate the clinical features 
of HCC-CC and the impact of resection margin width on 
patient survival.
MATERIALS AND METHODS
Data of consecutive patients who underwent hepa-
tectomy for hepatic malignancies in the period from 1995 
to 2014 were reviewed. Patients included for analysis 
were those who: (1) had pathologically confirmed HCC-
CC; (2) were not younger than 18 years; and (3) did 
not receive re-resection for recurrent HCC-CC. Diagnosis 
of HCC-CC was made by a combination of histological 
and immunohistochemical staining[22,23], supplemented 
by electron microscopy examination when necessary[11]. 
Demographic, biochemical, operative and pathological 
data were analyzed against survival outcomes. Cate-
gorical parameters were analyzed with Pearson’s χ2 test 
and continuous data were analyzed with the Mann-
Whitney U test. Univariate analysis with bivariate correla-
tion and multivariate analysis with the Cox regression 
model were performed. In this study, survival outcomes 
of HCC-CC were compared with the HCC and ICC patients 
of the same period. The Kaplan-Meier method was used 
for survival analysis and the log-rank test was used for 
survival comparison. P-values of ≤ 0.05 were considered 
statistically significant. The computer software Statistical 
Product and Service Solutions for Windows (SPSS, Chicago, 
Illinois, United States) was used for statistical analyses.
Perioperative care and follow-up protocol
Before hepatectomy, a basic biochemistry test was 
performed to assess complete blood picture, clotting 
profile, and liver and renal functions. Levels of tumor 
markers such as alpha-fetoprotein, carcinoembryonic 
antigen and cancer antigen 19-9 were recorded. Major 
637 May 8, 2017|Volume 9|Issue 13|WJH|www.wjgnet.com
hepatectomy was defined as resection of more than 3 
Couinaud segments. Indocyanine green retention rate at 
15 min after injection (ICG-R15) was used to evaluate 
the sufficiency of liver function for hepatectomy. For 
major hepatectomy, ICG-R15 of ≤ 18% was required. 
For minor hepatectomy, ICG-R15 of ≤ 22% was required. 
Patients having planned major hepatectomy were required 
to undergo computed tomographic volumetric study. The 
minimum ratio of future liver remnant to standard liver 
volume was 25% for non-cirrhotic livers[24,25]. Our technique 
of liver resection has been described elsewhere[24]. For 
follow-up, patients were seen at our out-patient clinic 
every 3 mo in the first 2 years and every 6 mo afterwards. 
Tumor markers were checked in every visit. Computed 
tomographic scan was performed 1-3 mo after discharge 
and then every 6 mo. Adjuvant therapy was not a routine 
and was offered at the discretion of the surgeon. Recur-
rence was defined as the presence of radiological or 
histological evidence of intrahepatic or extrahepatic HCC-CC.
RESULTS
From 1995 to 2014, 1696 patients underwent hepa-
tectomy for primary liver malignancy. Among them, 
50 adult patients had pathologically confirmed HCC-CC 
(3%). Eight of these 50 patients were excluded because 
of re-resection. As a result, 42 patients were included for 
analysis. Their demographic characteristics and baseline 
biochemistry are shown in Table 1.
Operative and pathological results
Most of the patients required major hepatectomy, and 
right hepatectomy was the most commonly performed 
procedure. Hepaticojejunostomy was performed in 6 
patients (Table 2). The median operation time was 414 min 
(range, 177-1149 min) and the median blood loss volume 
was 800 mL (range, 5-2400 mL). There was no hospital 
death. The median length of hospital stay was 13 d 
(range, 3-50 d). Three patients developed postoperative 
complications of Clavien-Dindo grade 3a or above (grade 
3a in 1 patient and grade 4 in 2 patients).
Histological examination was performed for all patients. 
The median tumor size was 6.5 cm (range, 2-23 cm). 
Twenty patients (47.6%) had multiple (more than 1) 
tumor nodules. Moderate tumor differentiation (new 
Edmondson grading) was found in 40% of the patients 
and 33.3% of the patients had poor tumor differentiation. 
R0 resection was achieved in 90% of the patients. The 
median resection margin width was 1 cm (range, 0-6 cm).
Survival outcomes and related factors
The median follow-up period was 110 mo. Adjuvant 
treatment was given to 13 patients in the form of 
transarterial chemo- or radio-embolization, systemic 
chemotherapy, external radiotherapy, molecular targeted 
therapy, or a combination of any of these. When it 
comes to survival outcomes, HCC-CC patients compared 
unfavorably with HCC patients. The median overall 
survival was 32 mo in HCC-CC patients and 70 mo in 
HCC patients (Figure 1A), and the median disease-free 
survival was 9 mo in the former and 28 mo in the latter 
(Figure 1B). On the other hand, HCC-CC patients and 
ICC patients had comparable overall survival (a median 
of 27 mo in ICC patients) (Figure 1C) while the latter had 
better disease-free survival (median, 20 mo) (Figure 1D). 
Recurrence developed in 33 HCC-CC patients (78.6%) 
(14 had intrahepatic recurrence, 3 had extrahepatic 
recurrence, and 16 had both).
In Cox regression analysis, tumor multiplicity was the 
only independent factor associated with overall survival 
[P < 0.001, odds ratio (OR) 5.26, 95%CI: 2.254-12.290] 
and disease-free survival (P = 0.001, OR 4.00, 95%CI: 
1.897-8.434) (Table 3). Patients with solitary tumor 
nodule had a median overall survival of 106 mo whereas 
those with multiple tumor nodules had a median overall 
survival of 16 mo (P < 0.001) (Figure 2A). The median 
disease-free survival was 19.2 mo in patients with solitary 
tumor nodule and 3.1 mo in patients with multiple tumor 
nodules (P < 0.001) (Figure 2B). 
Further analyses of the subgroup of patients (n = 
20) who had multiple tumor nodules were performed. In 
univariate analysis, disease-free survival had an association 
with preoperative albumin level (P = 0.022) and resection 
margin width (P = 0.013). Multivariate analysis showed 
No. of patients = 42
Male:female 29:13
Age (yr) 52.5 (26-72)
Hepatitis B virus carrier    31 (73.8%)
Hepatitis C virus carrier 0
Hemoglobin (g/dL)     13.4 (8.6-16.7)
White cell count (10 × 6/L)      5.8 (3.5-10.1)
Platelet count (10 × 9/L)   185 (89-499)
Creatinine (mmol/L)     84 (61-131)
Total bilirubin (mmol/L)  10 (2-61)
Albumin (g/L)    40 (29-49)
Aspartate transaminase (umol/L)      44 (14-270)
Alkaline phosphatase (umol/L)      92 (26-516)
Prothrombin time (s)       13.5 (10.9-13.5)
Alpha-fetoprotein (u/L)       75.5 (2-219020)
Carcinoembryonic antigen (u/L)     2.3 (0.4-5.9)
Table 1  Demographic characteristics and baseline biochemistry 
of the study population
Data are presented as median (range) unless otherwise stated.
No. of patients (%)
Right/extended right hepatectomy 17 (40.5)
Left/extended left hepatectomy   5 (11.9)
Right trisectionectomy   6 (14.3)
Left trisectionectomy 1 (2.4)
Central bisectionectomy 2 (4.8)
Left lateral sectionectomy 3 (7.1)
Other minor hepatectomy   8 (19.0)
Table 2  Types of operative procedure performed
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that resection margin width was the only independent 
factor affecting disease-free survival. A clear resection 
margin of ≥ 1 cm could improve 1-year disease-free 
survival from 0% to 40% (P = 0.012) (Figure 3).
Factor Overall survival (P -value) Disease-free survival (P -value)
Univariate Multivariate Univariate Multivariate
Age  0.269 NS    0.501 NS
Sex  0.513 NS    0.868 NS
HBV status  0.507 NS    0.441 NS
Platelet count  0.389 NS    0.331 NS
Total bilirubin  0.471 NS    0.176 NS
Albumin  0.811 NS    0.663 NS
ICG-R15  0.955 NS    0.749 NS
AFP  0.937 NS    0.308 NS
CEA  0.832 NS    0.716 NS
Operation time  0.239 NS    0.682 NS
Blood loss  0.138 NS    0.037 NS
Resection extent1  0.152 NS    0.108 NS
Tumor size  0.845 NS    0.975 NS
Multifocality < 0.0001 < 0.001   < 0.0001 0.001
Margin width  0.523 NS 0.9 NS
Wide margin (≥ 1 cm)  0.491 NS    0.096 NS
Microvascular invasion  0.373 NS    0.170 NS
Nodal metastasis  0.314 NS    0.229 NS
Adjuvant treatment  0.162 NS    0.052 NS
1Major vs minor. NS: Not significant; HBV: Hepatitis B virus; ICG-R15: Indocyanine green retention rate at 15 min after injection; AFP: Alpha-fetoprotein; 
CEA: Carcinoembryonic antigen.
Table 3  Cox regression analysis for factors affecting overall and disease-free survival
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Figure 1  Survival comparisons between different groups of patients. A: Overall survival of HCC-CC patients and HCC patients; B: Disease-free survival of HCC-
CC patients and HCC patients; C: Overall survival of HCC-CC patients and ICC patients; D: Disease-free survival of HCC-CC patients and ICC patients. HCC-CC: 
Hepatocholangiocarcinoma; ICC: Intrahepatic cholangiocarcinoma.
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DISCUSSION
This retrospective study has further illustrated that HCC-
CC is a rare and sinister primary hepatic malignancy. 
The reported incidences of HCC-CC vary greatly. This 
is probably due to the difference in the pathological 
definition of the disease. HCC-CC shares the clinicopatho-
logical features of HCC and ICC. Male predominance, the 
existence of background cirrhosis and elevation of alpha-
fetoprotein level are hallmarks of HCC. These features 
are also often seen in HCC-CC. Tumor hypovascularity, 
involvement of regional lymphadenopathy and poor 
survival outcomes are common in HCC-CC as well as ICC. 
This study found that HCC-CC patients had significantly 
worse overall survival and disease-free survival when 
compared with HCC patients, which concurs with other 
reports[26-29]. When compared with ICC patients, HCC-
CC patients had inferior disease-free survival but were 
comparable in overall survival. This explains why HCC-
CC should be included in the section of carcinoma of the 
intrahepatic duct in the 7th edition of the AJCC cancer 
staging manual[30]. The worse survival outcomes were 
attributable to its propensity for vascular invasion and 
lymph node metastasis[1,9,31].
Despite the availability of the various classification 
systems for HCC-CC[8,9,32], its prognosis remains difficult. 
Chantajitr et al[33] reported that a cancer antigen 19-9 
level of ≥ 80 u/mL and the presence of intrahepatic ductal 
dilatation were independent factors for poor survival. 
Other studies found that lymphovascular permeation, 
large tumor size and the presence of tumor satellites were 
poor prognostic factors[4,34-37]. In the current study, tumor 
multiplicity was the only independent factor associated 
with inferior disease-free survival and overall survival. 
This echoes the emphasis on the significance of tumor 
multiplicity in the staging of ICC in the 7th edition of 
the AJCC Staging[30]. The role of adjuvant therapy in 
HCC-CC management is still unclear. One fourth of the 
patients in the current study received some form of 
adjuvant treatment (transarterial chemoembolization, 
radiotherapy, systemic therapy, etc.) at the discretion 
of the surgeon. Standardization of adjuvant treatment 
protocol is necessary before the role of adjuvant therapy 
can be established.
The current study could not demonstrate any benefit 
of R0 resection for patients with resectable HCC-CC, 
probably because of the small number of patients with R1 
or R2 resection. Since HCC-CC is intrinsically associated 
with poorer prognostic outcomes when compared with 
HCC and ICC, small survival advantage conferred by wide 
resection margin (1 cm or above) could only be shown 
with a larger study population. However, this survival 
benefit was demonstrated in the subgroup of patients who 
had multifocal disease (40% vs 0% disease-free survival 
at 1 year). Since HCC-CC inherits the tumor biology of 
HCC and ICC, it has the ability of portal vein invasion 
and lymphovascular permeation. We therefore postulate 
that wide resection or even routine anatomical resection 
would eliminate residual satellite tumor cells or microtumor 
residing in the same vasculobiliary territory, thereby 
improving disease-free survival. The retrospective nature 
of the current study has posed a couple of limitations. 
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Figure 2  Survival of hepatocholangiocarcinoma patients with solitary vs multiple tumor nodules. A: Overall survival of HCC-CC patients with solitary 
tumor nodule and with multiple tumor nodules; B: Disease-free survival of HCC-CC patients with solitary tumor nodule and with multiple tumor nodules. HCC-CC: 
Hepatocholangiocarcinoma.
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patients with multifocal hepatocholangiocarcinoma.
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Firstly, missing data on carbohydrate antigen 19-9 made 
adequate analysis of its influence on survival outcomes 
impossible. In most of the cases, HCC-CC was diagnosed 
as HCC and routine blood check for carbohydrate antigen 
19-9 was clinically irrelevant. Secondly, the small cohort 
size predisposed the study to type-Ⅱ error; some 
potentially significant factors related to survival outcomes 
might not be identified by the analysis. However, the 
study period spanned two decades (1995-2014), which 
is relatively long. Furthermore, survival comparison 
between the study cohort and two much larger groups 
of patients (1536 HCC patients and 110 ICC patients) 
was performed, which should provide important data 
reference for future research.
HCC-CC is a rare and sinister primary hepatic mali-
gnancy. Patients with solitary tumor had better survival. 
A resection margin of at least 1 cm improved the disease-
free survival of patients with multiple tumor nodules.
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